IKT
Companies
NASDAQ
Inhibikase Therapeutics Inc.
Health Care
$1.68
-$1.57 (-48.31%)
Price Chart
Overview
About IKT
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Market Cap
$13.4M
Volume
204.9K
Avg. Volume
199.8K
P/E Ratio
-7.96
Dividend Yield
0.00%
Employees
5.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.60
Low Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, IKT shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$13.4M
Volume204.9K
P/E Ratio-7.96
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 15, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025